Antifungal treatment for talaromycosis in HIV patients
Treatments studied
Part of Infections clinical trials.
This trial compares two antifungal medicines to treat talaromycosis, a serious fungal infection common in people with HIV. It tests whether a shorter course of treatment with two medicines is as good as the standard approach, which may help reduce side effects and hospital time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be HIV-positive and 18 years or older.
- You must have a confirmed diagnosis of talaromycosis (a fungal infection) through lab tests.
- You can be on or off HIV treatment (ART).
- You cannot be pregnant, have a severe allergy to the study drugs, have a low white blood cell count (below 500), or have another serious infection like cryptococcal or TB meningitis.
- You must not have already received more than 2 doses of a certain antifungal drug (DAmB).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time high dose of an antifungal medicine (liposomal amphotericin B) combined with a standard HIV treatment (B/F/TAF) for people with HIV who also have talaromycosis, a serious fungal infection. The goal is to see if this approach is safe and effective.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This Phase 3 trial tests whether a high-dose form of amphotericin B made in tiny fat particles (liposomal amphotericin B) is safer and more effective for treating widespread Histoplasmosis in adults with HIV. It may help people who have a serious, whole-body infection caused by Histoplasma.
This study tests whether a shorter course of an antifungal drug (fluconazole) plus earlier HIV treatment is safe and works as well as the standard approach for people with HIV who have a low level of cryptococcal antigen in their blood. It aims to prevent a serious fungal infection from developing.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
Hear when a new Talaromycosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.